Fairvalue-Calculator Fairvalue-Calculator
EN DE

Clinuvel Pharmaceuticals Limited (CUV) Fair Value & Analysis

Healthcare · AU · Market cap A$460M

PriceA$9.95
Fair ValueA$15.78
Upside+58.6%
Quality95/100
Evidence: High Range A$11.84 – A$19.73

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Clinuvel Pharmaceuticals Limited (CUV) currently trades at A$9.95, while our model-based Fair Value estimate is A$15.78 — implying the stock looks roughly 58.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Clinuvel Pharmaceuticals Limited (CUV) undervalued?
As of Jun 24, 2026, our model estimates a fair value of A$15.78 versus a price of A$9.95 — about +59% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CUV?
Our 21-model fair value for Clinuvel Pharmaceuticals Limited is A$15.78 (as of Jun 24, 2026), built from audited fundamentals. The current price is A$9.95.
What is the quality score of CUV?
Clinuvel Pharmaceuticals Limited has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.